RecruitingPhase 2NCT07513285

ACX-362E [Ibezapolstat] for Oral Treatment of Recurrent Clostridioides Difficile Infection

A Phase 2 Interventional, Open-Label, Single-Arm Trial of Oral Ibezapolstat (ACX-362E) for Treatment and Reduction of Recurrent Clostridioides Difficile Infection in Patients With Multiple Recurrent Infections (IBZ-PATHFINDER)

Sponsor

Acurx Pharmaceuticals Inc.

Enrollment

20 participants

Start Date

Aug 6, 2026

Study Type

INTERVENTIONAL

Conditions

Clostridium Difficile Infection Recurrence

Summary

Single-arm trial to evaluate the safety and efficacy of ACX-362E \[ibezapolstat\] in patients with recurrent C. difficile infection (CDI).

Eligibility

Min Age: 18 YearsMax Age: 90 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Ibezapolstat for people with clostridium difficile infection recurrence. The study is currently recruiting participants at 15 locations. People eligible for this study include aged 18 Years to 90 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGIbezapolstat

Ibezapolstat 450 mg po Q12H x14 days

Locations(15)

UC Davis Medical Center

Sacramento, California, United States

Gastroenterolgy Center of Conneticut

Hamden, Connecticut, United States

Florida International Medical Research

Coral Gables, Florida, United States

L&A Morales Healthcare, Inc

Hialeah, Florida, United States

San Marcus Research Clinc, Inc

Miami Lakes, Florida, United States

Belis Delgado, MD PA

Miami Springs, Florida, United States

Infectious Disease Consultants of Georgia

Athens, Georgia, United States

Snake River Research PLLC

Idaho Falls, Idaho, United States

Endevour Health

Skokie, Illinois, United States

Newton-Wellesley Hospital

Newton, Massachusetts, United States

University of Massachusetts Memorial Healthcare

Worcester, Massachusetts, United States

Henry Ford Hospital

Detroit, Michigan, United States

DiGiovanna Institute for Medical Education and Research

Massapequa, New York, United States

Romano, Pontzer & Associated

Pittsburgh, Pennsylvania, United States

University of Utah

Salt Lake City, Utah, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07513285

Related Trials

VE303 for Prevention of Recurrent Clostridioides Difficile Infection

NCT06237452215 locations

Outcomes and Data Collection for Fecal Microbiota Transplantation for the Treatment of Recurrent Clostridium Difficile

NCT035627411 location

Real-World Study on Fecal Microbiota Transplantation: Long-Term Effectiveness and Safety Statistics

NCT072618261 location